Arlington Financial Advisors LLC Invests $2.05 Million in iShares Biotechnology ETF (NASDAQ:IBB)

Arlington Financial Advisors LLC bought a new stake in shares of iShares Biotechnology ETF (NASDAQ:IBB) in the fourth quarter, Holdings Channel reports. The institutional investor bought 15,524 shares of the financial services provider’s stock, valued at approximately $2,052,000.

A number of other institutional investors and hedge funds have also recently modified their holdings of IBB. Darwin Wealth Management LLC bought a new stake in shares of iShares Biotechnology ETF in the 3rd quarter valued at approximately $29,000. Highline Wealth Partners LLC purchased a new stake in iShares Biotechnology ETF during the 3rd quarter valued at $30,000. HHM Wealth Advisors LLC raised its holdings in iShares Biotechnology ETF by 200.0% during the 4th quarter. HHM Wealth Advisors LLC now owns 225 shares of the financial services provider’s stock valued at $30,000 after buying an additional 150 shares during the period. Ashton Thomas Securities LLC bought a new stake in iShares Biotechnology ETF in the third quarter worth $36,000. Finally, Hager Investment Management Services LLC purchased a new position in iShares Biotechnology ETF during the fourth quarter worth $34,000. 62.45% of the stock is owned by hedge funds and other institutional investors.

iShares Biotechnology ETF Trading Down 2.1 %

Shares of NASDAQ IBB opened at $137.67 on Friday. iShares Biotechnology ETF has a fifty-two week low of $123.60 and a fifty-two week high of $150.57. The business’s 50 day moving average price is $136.22 and its 200-day moving average price is $141.41.

iShares Biotechnology ETF Cuts Dividend

The firm also recently announced a dividend, which was paid on Friday, December 20th. Shareholders of record on Tuesday, December 17th were paid a $0.0624 dividend. The ex-dividend date of this dividend was Tuesday, December 17th.

About iShares Biotechnology ETF

iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ.